Vivos Therapeutics (NASDAQ:VVOS) Cut to “Hold” at Zacks Investment Research


Share on StockTwits

Zacks Investment Research lowered shares of Vivos Therapeutics (NASDAQ:VVOS) from a buy rating to a hold rating in a research report sent to investors on Saturday, Zacks.com reports.

According to Zacks, “Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado. “

A number of other research analysts have also recently commented on the stock. Craig Hallum initiated coverage on shares of Vivos Therapeutics in a research report on Monday, January 11th. They issued a buy rating and a $12.00 target price on the stock. Roth Capital started coverage on shares of Vivos Therapeutics in a research report on Tuesday, January 5th. They issued a buy rating and a $12.00 target price on the stock.

NASDAQ VVOS opened at $6.57 on Friday. The firm has a 50-day moving average of $7.75. Vivos Therapeutics has a 12 month low of $5.64 and a 12 month high of $14.41.

Vivos Therapeutics (NASDAQ:VVOS) last posted its earnings results on Thursday, March 25th. The company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.27). The business had revenue of $3.30 million for the quarter, compared to the consensus estimate of $2.92 million.

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Vivos Therapeutics during the fourth quarter worth about $191,000. Walleye Capital LLC acquired a new stake in Vivos Therapeutics in the fourth quarter valued at approximately $440,000. Royce & Associates LP acquired a new stake in Vivos Therapeutics in the fourth quarter valued at approximately $1,773,000. K.J. Harrison & Partners Inc acquired a new stake in Vivos Therapeutics in the fourth quarter valued at approximately $540,000. Finally, Perkins Capital Management Inc. acquired a new stake in Vivos Therapeutics in the fourth quarter valued at approximately $118,000.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA.

Recommended Story: What can cause a stock to outperform?

Get a free copy of the Zacks research report on Vivos Therapeutics (VVOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.